Zhi Peng

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 7

Top Topics

Metastatic Colorectal Cancer

Top Venues

Cancer biology & medicine

International journal of colorectal disease

Hereditary cancer in clinical practice

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Yifan Zhang, Lin Shen, Zhi Peng
Advances in MET tyrosine kinase inhibitors in gastric cancer. Cancer biology & medicine 21 (6) (2024)
Yifan Zhang, Lin Shen, Zhi Peng
Advances in MET tyrosine kinase inhibitors in gastric cancer. Cancer biology & medicine (2024)
Yifan Zhang, Lin Shen, Zhi Peng
Advances in MET tyrosine kinase inhibitors in gastric cancer. Cancer biology & medicine 21 (6) (2024)
Tong Xie, Zhening Zhang, Changsong Qi, Ming Lu, Xiaotian Zhang, Jian Li, Lin Shen, Zhi Peng
The Inconsistent and Inadequate Reporting Of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials. The oncologist 26 (12) (2021)
Panpan Zhang, Zhongwu Li, Jie Li, Jian Li, Xiaotian Zhang, Zhihao Lu, Yu Sun, Yan Li, Jun Zhou, Xicheng Wang, Zhi Peng, Lin Shen, Ming Lu
Clinicopathological features and lymph node and distant metastasis patterns in patients with gastroenteropancreatic mixed neuroendocrine-non-neuroendocrine neoplasm. Cancer medicine 10 (14) (2021)
Tong Xie, Qin Feng, Zhongwu Li, Ming Lu, Jian Li, Analyn Lizaso, Jianxing Xiang, Lu Zhang, Lin Shen, Zhi Peng
Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review. Hereditary cancer in clinical practice 19 (1) (2021)
Qi Zhang, Qianqian Wang, Xicheng Wang, Jian Li, Lin Shen, Zhi Peng
Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials? International journal of colorectal disease 35 (2) (2019)